HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions Constitutionality Of Proposed CIR Bridge, A Blow To CMA Bill

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Modernization Amendments of 2015 is touted by small business as a more appropriately sized update to the regulatory framework than the front-running PCPSA. However, some provisions seen as vital are absent from the bill, while its call for FDA to accept CIR safety decisions could be deemed unconstitutional, an FDA official suggests in a letter to Senate HELP Committee Chair Lamar Alexander.

You may also be interested in...



California’s Toxic Free Cosmetics Act And The Case For Iconclad Federal Preemption

Limited to no federal preemption is included in cosmetics bills under consideration in the 116th Congress, which means that even if one were to pass in its current form, companies could still be at the mercy of states, typically California, imposing unique bans or restrictions on cosmetic ingredients.

Cosmetic Ingredient Review Program Will Get 'Fresh Look' In 2018 – PCPC

With federal legislation on the table to task FDA with cosmetic ingredient reviews and provide accredited third parties with the opportunity to inform the agency's assessment work, the Personal Care Products Council plans to give the industry-funded Cosmetic Ingredient Review program a "fresh look."

CIR Director Gill Steps Down, Leaving Legacy Of Improved Transparency

Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.

Related Content

Topics

UsernamePublicRestriction

Register

RS108667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel